BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 23741342)

  • 1. Fatty acid synthase is a key target in multiple essential tumor functions of prostate cancer: uptake of radiolabeled acetate as a predictor of the targeted therapy outcome.
    Yoshii Y; Furukawa T; Oyama N; Hasegawa Y; Kiyono Y; Nishii R; Waki A; Tsuji AB; Sogawa C; Wakizaka H; Fukumura T; Yoshii H; Fujibayashi Y; Lewis JS; Saga T
    PLoS One; 2013; 8(5):e64570. PubMed ID: 23741342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines.
    Hill TK; Davis AL; Wheeler FB; Kelkar SS; Freund EC; Lowther WT; Kridel SJ; Mohs AM
    Mol Pharm; 2016 Mar; 13(3):720-8. PubMed ID: 26824142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer.
    Migita T; Ruiz S; Fornari A; Fiorentino M; Priolo C; Zadra G; Inazuka F; Grisanzio C; Palescandolo E; Shin E; Fiore C; Xie W; Kung AL; Febbo PG; Subramanian A; Mucci L; Ma J; Signoretti S; Stampfer M; Hahn WC; Finn S; Loda M
    J Natl Cancer Inst; 2009 Apr; 101(7):519-32. PubMed ID: 19318631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells.
    Wen S; Niu Y; Lee SO; Yeh S; Shang Z; Gao H; Li Y; Chou F; Chang C
    Mol Carcinog; 2016 Dec; 55(12):2278-2290. PubMed ID: 26894509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of fatty acid synthase in human gliomas correlates with the WHO tumor grade and inhibition with Orlistat reduces cell viability and triggers apoptosis.
    Grube S; Dünisch P; Freitag D; Klausnitzer M; Sakr Y; Walter J; Kalff R; Ewald C
    J Neurooncol; 2014 Jun; 118(2):277-287. PubMed ID: 24789255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatty Acid Inhibition Sensitizes Androgen-Dependent and -Independent Prostate Cancer to Radiotherapy via FASN/NF-κB Pathway.
    Chuang HY; Lee YP; Lin WC; Lin YH; Hwang JJ
    Sci Rep; 2019 Sep; 9(1):13284. PubMed ID: 31527721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy.
    Schcolnik-Cabrera A; Chávez-Blanco A; Domínguez-Gómez G; Taja-Chayeb L; Morales-Barcenas R; Trejo-Becerril C; Perez-Cardenas E; Gonzalez-Fierro A; Dueñas-González A
    Expert Opin Investig Drugs; 2018 May; 27(5):475-489. PubMed ID: 29723075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of orlistat combined with enzalutamide and castration through inhibition of fatty acid synthase in a PC3 tumor-bearing mouse model.
    Tyan YS; Lee YP; Chuang HY; Wang WH; Hwang JJ
    Biosci Rep; 2021 May; 41(5):. PubMed ID: 33974005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The fatty acid synthase inhibitor orlistat reduces the growth and metastasis of orthotopic tongue oral squamous cell carcinomas.
    Agostini M; Almeida LY; Bastos DC; Ortega RM; Moreira FS; Seguin F; Zecchin KG; Raposo HF; Oliveira HC; Amoêdo ND; Salo T; Coletta RD; Graner E
    Mol Cancer Ther; 2014 Mar; 13(3):585-95. PubMed ID: 24362464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate cancer.
    Sadowski MC; Pouwer RH; Gunter JH; Lubik AA; Quinn RJ; Nelson CC
    Oncotarget; 2014 Oct; 5(19):9362-81. PubMed ID: 25313139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic shifts induced by fatty acid synthase inhibitor orlistat in non-small cell lung carcinoma cells provide novel pharmacodynamic biomarkers for positron emission tomography and magnetic resonance spectroscopy.
    Sankaranarayanapillai M; Zhang N; Baggerly KA; Gelovani JG
    Mol Imaging Biol; 2013 Apr; 15(2):136-47. PubMed ID: 22886728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orlistat Reduces Proliferation and Enhances Apoptosis in Human Pancreatic Cancer Cells (PANC-1).
    Sokolowska E; Presler M; Goyke E; Milczarek R; Swierczynski J; Sledzinski T
    Anticancer Res; 2017 Nov; 37(11):6321-6327. PubMed ID: 29061815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas.
    Seguin F; Carvalho MA; Bastos DC; Agostini M; Zecchin KG; Alvarez-Flores MP; Chudzinski-Tavassi AM; Coletta RD; Graner E
    Br J Cancer; 2012 Sep; 107(6):977-87. PubMed ID: 22892389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy with fatty acid synthase inhibitors in a human prostate carcinoma LNCaP/tk-luc-bearing animal model.
    Chen HW; Chang YF; Chuang HY; Tai WT; Hwang JJ
    Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):260-4. PubMed ID: 22565411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring a role for fatty acid synthase in prostate cancer cell migration.
    De Piano M; Manuelli V; Zadra G; Loda M; Muir G; Chandra A; Morris J; Van Hemelrijck M; Wells CM
    Small GTPases; 2021 Jul; 12(4):265-272. PubMed ID: 33043786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Tumorigenic Potential of a Novel Orlistat-AICAR Combination in Prostate Cancer Cells.
    Wright C; Iyer AKV; Kaushik V; Azad N
    J Cell Biochem; 2017 Nov; 118(11):3834-3845. PubMed ID: 28387458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FASN Inhibition and Taxane Treatment Combine to Enhance Anti-tumor Efficacy in Diverse Xenograft Tumor Models through Disruption of Tubulin Palmitoylation and Microtubule Organization and FASN Inhibition-Mediated Effects on Oncogenic Signaling and Gene Expression.
    Heuer TS; Ventura R; Mordec K; Lai J; Fridlib M; Buckley D; Kemble G
    EBioMedicine; 2017 Feb; 16():51-62. PubMed ID: 28159572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of fatty acid synthase suppresses neovascularization via regulating the expression of VEGF-A in glioma.
    Zhou Y; Jin G; Mi R; Zhang J; Zhang J; Xu H; Cheng S; Zhang Y; Song W; Liu F
    J Cancer Res Clin Oncol; 2016 Dec; 142(12):2447-2459. PubMed ID: 27601165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model.
    Papaevangelou E; Almeida GS; Box C; deSouza NM; Chung YL
    Int J Cancer; 2018 Aug; 143(4):992-1002. PubMed ID: 29569717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatty acid synthase expression and esophageal cancer.
    Zhou Y; Niu C; Li Y; Gao B; Zheng J; Guo X; Ma W
    Mol Biol Rep; 2012 Oct; 39(10):9733-9. PubMed ID: 22723001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.